New Parkinson’s Pill Offers Hope Early days but plenty of encouragement

October 16, 2026

Discover a Parkinson’s Pill that may herald a major breakthrough

A new once-a-day pill for Parkinson’s disease has produced encouraging results in a major clinical trial — potentially opening up a completely new way of treating the condition.

The drug, called solengepras, reduced the amount of time people experienced troublesome movement symptoms such as stiffness, slowness and tremors.

It also appeared to help people stay more alert during the day and made everyday activities such as dressing, eating and getting around easier.

Why is this different?

For more than 50 years, most Parkinson’s medicines have focused on dopamine, a chemical messenger in the brain that plays an important role in controlling movement.

The best-known treatment, levodopa, has been used since the 1960s. The body converts it into dopamine, helping to compensate for what the brain has lost.

It can be extremely effective, but as Parkinson’s progresses its benefits can become less predictable.

People may experience periods when their medication wears off and symptoms return. These are known as “off” periods. Higher doses can also contribute to involuntary movements known as dyskinesia.

A completely different approach

Solengepras does not work by increasing dopamine.

Instead, it blocks a receptor in the brain called GPR6, which is involved in a movement-control circuit.

One way of thinking about it is as a brake. In Parkinson’s, the loss of dopamine can cause this braking system to become too strong, making movement more difficult. Solengepras is designed to ease that brake.

That makes the drug particularly interesting because it could represent a new class of Parkinson’s treatment rather than another variation on existing dopamine-based medicines.

What did the trial find?

The Phase 3 trial involved 341 people with Parkinson’s, who received either solengepras or a placebo once a day for 12 weeks. They continued taking their existing Parkinson’s medication.

Those receiving the higher dose of solengepras experienced:

37 minutes less “off” time each day compared with people taking the placebo — and around 94 minutes less than before the trial began.

They also gained around 36 additional minutes of good “on” time each day without troublesome involuntary movements, compared with the placebo group.

There were other encouraging signs. Participants reported improvements in everyday activities, less daytime sleepiness and better overall quality of life.

What about side effects?

The drug appeared to be well tolerated during the 12-week study.

No serious adverse events were reported, and 3.5% of participants taking the drug stopped because of side effects — the same proportion as those taking the placebo.

Longer-term studies and regulatory scrutiny will still be important before its full safety and effectiveness can be established.

When could it become available?

Solengepras is not yet an approved treatment.

The developers are expected to discuss the results with US regulators, with the UK potentially following. If further development and regulatory approval proceed successfully, reports suggest it could potentially become available within the next two to three years.

Why this could matter

There are around 166,000 people diagnosed with Parkinson’s in the UK, with others thought to be living with the condition without knowing it.

Solengepras isn’t being presented as a cure, and the trial tested it alongside existing Parkinson’s medicines rather than replacing them.

But its importance may lie in something bigger: it attacks Parkinson’s symptoms through a different biological pathway.

After decades in which treatment has largely revolved around dopamine, that could provide doctors with another tool for helping people remain mobile, independent and active for longer.

Solengepras needs regulatory approval and further evidence before it can become part of routine Parkinson’s care. What makes the development exciting is not simply another new pill — but a potentially new way of treating Parkinson’s.

One of the most common afflications for the elderly is a stroke, so find out how to spot the signs which could make all the difference.